Cargando…

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment

Currently, there is no specific antiviral treatment for COVID-19. However, drugs previously developed to treat other viral infections are being tested to verify if they might also be effective against SARS-CoV-2, the virus that causes COVID-19. Twenty years ago, the F.D.A. approved Lopinavir/ritonav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magro, Paola, Zanella, Isabella, Pescarolo, Marta, Castelli, Francesco, Quiros-Roldan, Eugenia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chang Gung University 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654234/ https://www.ncbi.nlm.nih.gov/pubmed/33608241 http://dx.doi.org/10.1016/j.bj.2020.11.005

Ejemplares similares

Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection
por: Zanella, Isabella, et al.
Publicado: (2021)

Correction: Zanella et al. Tenofovir, Another Inexpensive, Well Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. Pharmaceuticals 2021, 14, 454
por: Zanella, Isabella, et al.
Publicado: (2021)

The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
por: Quiros Roldan, Eugenia, et al.
Publicado: (2020)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
por: Chandwani, Ashish, et al.
Publicado: (2008)

The impact of antiretroviral therapy on iron homeostasis and inflammation markers in HIV-infected patients with mild anemia
por: Quiros-Roldan, Eugenia, et al.
Publicado: (2017)

Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
por: Martinez, Beatriz Larru, et al.
Publicado: (2010)

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
Publicado: (2015)

Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

An HIV elite controller patient carrying the homozygous H63D variant in the homeostatic iron regulator gene: A case report
por: Zanella, Isabella, et al.
Publicado: (2021)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

High frequency of type I interferon auto‐antibodies in a group of middle‐aged HIV‐infected patients: A cross‐sectional exploratory study
por: Imberti, Luisa, et al.
Publicado: (2023)

Non-neutralizing antibodies: Deleterious or propitious during SARS-CoV-2 infection?
por: Zanella, Isabella, et al.
Publicado: (2022)

High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment
por: Macías, Juan, et al.
Publicado: (2020)

Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa
por: Murphy, Richard A., et al.
Publicado: (2012)

Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications
por: Agarwal, Shubham, et al.
Publicado: (2020)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir()
por: Brandariz-Nuñez, David, et al.
Publicado: (2020)

Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2011)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
por: Zhang, C, et al.
Publicado: (2010)

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2012)

Correction: Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa
por: Murphy, Richard A., et al.
Publicado: (2013)

Assessing the adoption of lopinavir/ritonavir oral pellets for HIV‐positive children in Zimbabwe
por: Pasipanodya, Briony, et al.
Publicado: (2018)

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
por: Owa, Adewale Bayode, et al.
Publicado: (2020)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

The administration of lopinavir/ritonavir via an enteral feeding tube()
por: Sirvent Segovia, Alejandro Esteban, et al.
Publicado: (2021)

The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy
por: Decloedt, Eric H., et al.
Publicado: (2012)

The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients
por: Kredo, T., et al.
Publicado: (2016)

Comparable Long-Term Efficacy of Lopinavir/Ritonavir and Similar Drug-Resistance Profiles in Different HIV-1 Subtypes
por: Grossman, Zehava, et al.
Publicado: (2014)

HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir
por: Sutherland, K. A., et al.
Publicado: (2015)

Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis
por: Tigabu, Bereket Molla, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qgidtlplck5a6lg08frddcqs6l